NEW YORK, March 27, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Omnicare Inc. (NYSE: OCR), The Cooper Companies Inc. (NYSE: COO),
MEDNAX, Inc. (NYSE: MD), IDEXX Laboratories, Inc. (NASDAQ: IDXX),
and Hologic Inc. (NASDAQ: HOLX). Private wealth members receive
these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Omnicare Inc. Analyst Notes
On March 21, 2014, Omnicare Inc.
(Omnicare) announced that Advanced Care Scripts (ACS), a division
of Omnicare Specialty Care Group, has been awarded Specialty
Pharmacy Accreditation from URAC. URAC is a Washington, DC-based health care accrediting
organization that establishes quality standards for the health care
industry. "ACS is proud to receive this accreditation," said
Amit Jain, Senior Vice President of
Sales and Marketing. "We are dedicated to providing quality care
and meeting the highest industry standards for our customers and
patients." ACS manages and dispenses specialty medications in
multiple disease categories, including cancer, infectious diseases,
auto-immune disorders, multiple sclerosis and hemophilia. The full
analyst notes on Omnicare Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03272014/OCR/report.pdf
--
The Cooper Companies Inc. Analyst Notes
On March 17, 2014, The Cooper
Companies Inc. (Cooper) announced at its annual meeting held on
March 17, 2014, that the stockholders
of the Company elected eight directors: A.
Thomas Bender, Allan E.
Rubenstein, M.D., Michael H.
Kalkstein, Jody S. Lindell,
Gary S. Petersmeyer, Steven Rosenberg, Robert
S. Weiss, and Stanley
Zinberg, M.D. and ratified the appointment of KPMG LLP as
the Company's auditors for FY 2014. The stockholders also approved,
on an advisory basis, the Company's compensation practices for its
executive officers. The full analyst notes on The Cooper Companies
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03272014/COO/report.pdf
--
MEDNAX, Inc. Analyst Notes
On March 4, 2014, MEDNAX Inc.
(MEDNAX) announced that it has acquired Piedmont Neonatology, P.C.,
a private neonatal physician group practice based in Greensboro, N.C. The practice will become part
of MEDNAX's Pediatrix Medical Group division, a national group
practice consisting of the nation's leading neonatal,
maternal-fetal medicine, pediatric cardiology, and other pediatric
specialty physicians. The practice was acquired for cash and the
transaction is expected to be immediately accretive to earnings. No
additional terms of the transaction were disclosed. The full
analyst notes on MEDNAX, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03272014/MD/report.pdf
--
IDEXX Laboratories, Inc. Analyst Notes
On March 11, 2014, IDEXX
Laboratories, Inc. (IDEXX) announced the election of Daniel M. Junius as a member of the Company's
Board of Directors, effective March 11,
2014. "I am very pleased and excited to welcome Daniel Junius to our Board of Directors," said
Jonathan Ayers, the Company's
Chairman of the Board and CEO. "Dan brings an impressive depth of
executive leadership, strategic thinking and financial experience
as well as extensive biotechnology knowledge, which the Company
will benefit from as it continues to strengthen and grow its
business and capitalize on its opportunities." Mr. Junius
previously served as President and CEO of ImmunoGen, Inc. The full
analyst notes on IDEXX Laboratories, Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/03272014/IDXX/report.pdf
--
Hologic Inc. Analyst Notes
On March 14, 2014, Hologic, Inc.
(Hologic) announced organizational and leadership changes in order
to achieve its corporate objectives including organic growth and
executional excellence across its global operations. The Company
appointed Eric Compton to the role
of Chief Operating Officer and will be responsible for overseeing
all of the Company's commercial operations in the US, as well as
the Company's global research and development, manufacturing and
service operations. Claus Egstrand has been named Senior Vice
President and General Manager, International, and will be
responsible for the Company's operations outside of the United States. David Harding, who previously served as
Hologic's Group Senior Vice President and General Manager of
Women's Health, has been named Senior Vice President of Corporate
Strategy. The full analyst notes on Hologic Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/03272014/HOLX/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review